Redhill Biopharma Ltd ADRRDHL
Price$0.48

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $8M+23.2% YoYTTM through 30 Jun 2025
Net Income -$8.3M-134.6% YoYTTM through 30 Jun 2025
Free Cash Flow -$9.4MTTM through 30 Jun 2025

Margins

Current
EBITDA Margin-174.4%
Operating Margin-2,633.3%
Net Margin-102.8%

Returns

-9.4%ROE
-1.6%ROA

Balance Sheet Health

Debt / Equity0.05x
Current Ratio0.34x
Net Debt-$3.8Mnet cash position
Cash & Equivalents$2.9M

Quality Metrics

Piotroski F-Score3 / 9
FCF Margin-116.6%
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'18'19'20'21'22'23'24
FY2024: $8M
Diluted EPS
'18'19'20'21'22'23'24
FY2024: $0.00

Dividend

No dividend

Capital Allocation

Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.